Zobrazeno 1 - 10
of 14
pro vyhledávání: '"James R Clem"'
Publikováno v:
Risk Management and Healthcare Policy, Vol 2010, Iss default, Pp 1-11 (2009)
James R Clem1, Joe D Strain2, Debra K Farver31South Dakota State University College of Pharmacy Sioux Falls, South Dakota, USA; 2South Dakota State University College of Pharmacy, Rapid City Regional Hospital, Rapid City, South Dakota, USA; 3South Da
Externí odkaz:
https://doaj.org/article/fab347ffb5f542f6b78cc31781ecc8d3
Autor:
Jerome W Freeman, Surachat Ngorsuraches, Diana I. Brixner, Natasha Frost, Jane R. Mort, James R Clem
Publikováno v:
Multiple sclerosis and related disorders. 35
Background While disease-modifying therapies (DMTs) for multiple sclerosis (MS) treatments are costly, patient valuation of DMTs has not been examined. The objective of this study was to examine patients' preferences and willingness-to-pay (WTP) for
Autor:
James R, Clem, Jodi, Heins
Publikováno v:
South Dakota medicine : the journal of the South Dakota State Medical Association. 70(4)
Publikováno v:
Clinical pharmacology : advances and applications
Mixed dyslipidemia, characterized by a lipid triad of elevated triglycerides (TG), elevated low-density lipoprotein-cholesterol (LDL-C) and reduced high-density lipoprotein-cholesterol (HDL-C), is a common and frequently difficult to manage condition
Publikováno v:
Risk Management and Healthcare Policy
Risk Management and Healthcare Policy, Vol 2010, Iss default, Pp 1-11 (2009)
Risk Management and Healthcare Policy, Vol 2010, Iss default, Pp 1-11 (2009)
James R Clem1, Joe D Strain2, Debra K Farver31South Dakota State University College of Pharmacy Sioux Falls, South Dakota, USA; 2South Dakota State University College of Pharmacy, Rapid City Regional Hospital, Rapid City, South Dakota, USA; 3South Da
Autor:
Laura, Johnson, James R, Clem
Publikováno v:
South Dakota medicine : the journal of the South Dakota State Medical Association. 66(9)
Autor:
James R, Clem
Publikováno v:
South Dakota medicine : the journal of the South Dakota State Medical Association. 64(7)
Autor:
James R, Clem
Publikováno v:
South Dakota medicine : the journal of the South Dakota State Medical Association. 63(8)
Publikováno v:
Current drug safety. 5(3)
Dronedarone is an oral Class III antiarrhythmic agent which was recently approved by the US Food and Drug Administration for use in nonpermanent atrial fibrillation. Structurally similar to amiodarone, dronedarone is a benzofuran derivative but it la
Autor:
James R, Clem
Publikováno v:
South Dakota medicine : the journal of the South Dakota State Medical Association. 61(4)